Olivier Negre

Chief Scientific Officer • Smart-Immune

Olivier Negre, Ph.D. developed his expertise in preclinical research and drug development through more than 20 years of experience in biotherapies. After working on recombinant vaccines with Bioprotein Technologies, he joined bluebird bio and contributed for 15 years to the development of the first approved gene therapy for beta-thalassemia. Scientist and Team Leader in Paris, France and became Director for Translational Research in Cambridge MA, USA. Back to France he co-founder Biotherapy Partners and participated in the HEC Challenge Plus training program. He is board member of the French Society of Gene and Cell Therapy and President of the think-tank Gene and Cell Therapy Institute (G&CTI). Currently Chief Scientific Officer at Smart Immune, he contributes to develop a new T-cell platform with applications in the field of hematopoietic stem cell transplant and cellular immuno-oncology.

Also Speaking

Bernd Leistler

Vice President Production • Sartorius CellGenix

Becky Johnson-Kent

Vice President, Europe & Women in Advanced Therapies (WiAT) Programme Lead • Phacilitate

Leonardo M.R. Ferreira

Assistant Professor of Microbiology and Immunology  • Medical University of South Carolina

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.